Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 12 studies | 62% ± 27% | |
GABAergic neuron | 10 studies | 55% ± 29% | |
oligodendrocyte precursor cell | 10 studies | 32% ± 15% | |
interneuron | 6 studies | 58% ± 28% | |
neuron | 5 studies | 34% ± 10% | |
astrocyte | 5 studies | 32% ± 21% | |
granule cell | 4 studies | 51% ± 19% | |
amacrine cell | 4 studies | 27% ± 8% | |
GABAergic interneuron | 3 studies | 55% ± 10% | |
retinal bipolar neuron | 3 studies | 20% ± 5% | |
retina horizontal cell | 3 studies | 18% ± 2% | |
rod bipolar cell | 3 studies | 33% ± 12% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 12 studies | 43% ± 25% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 92% | 445.96 | 600 / 653 | 61% | 1.24 | 370 / 605 |
brain | 93% | 1970.84 | 2454 / 2642 | 57% | 2.65 | 399 / 705 |
kidney | 87% | 365.24 | 77 / 89 | 14% | 0.34 | 130 / 901 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.70 | 1 / 1 |
pancreas | 81% | 231.15 | 265 / 328 | 14% | 0.49 | 25 / 178 |
adrenal gland | 17% | 112.00 | 44 / 258 | 45% | 2.29 | 104 / 230 |
bladder | 24% | 63.57 | 5 / 21 | 17% | 0.53 | 86 / 504 |
prostate | 22% | 58.33 | 55 / 245 | 16% | 0.24 | 80 / 502 |
ovary | 0% | 0 | 0 / 180 | 38% | 0.73 | 163 / 430 |
breast | 9% | 20.78 | 43 / 459 | 23% | 0.42 | 252 / 1118 |
intestine | 19% | 44.51 | 185 / 966 | 6% | 0.10 | 33 / 527 |
stomach | 8% | 20.91 | 30 / 359 | 7% | 0.21 | 21 / 286 |
lung | 4% | 8.32 | 26 / 578 | 10% | 0.22 | 118 / 1155 |
lymph node | 0% | 0 | 0 / 0 | 14% | 0.26 | 4 / 29 |
esophagus | 1% | 1.26 | 8 / 1445 | 12% | 0.25 | 22 / 183 |
uterus | 1% | 3.20 | 2 / 170 | 7% | 0.12 | 31 / 459 |
liver | 0% | 0 | 0 / 226 | 2% | 0.04 | 9 / 406 |
skin | 1% | 4.26 | 26 / 1809 | 1% | 0.01 | 3 / 472 |
eye | 0% | 0 | 0 / 0 | 1% | 0.01 | 1 / 80 |
peripheral blood | 1% | 1.72 | 6 / 929 | 0% | 0 | 0 / 0 |
adipose | 0% | 1.02 | 3 / 1204 | 0% | 0 | 0 / 0 |
heart | 0% | 0.77 | 2 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 0.28 | 1 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
GO_0007265 | Biological process | Ras protein signal transduction |
GO_0120162 | Biological process | positive regulation of cold-induced thermogenesis |
GO_0019722 | Biological process | calcium-mediated signaling |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0000165 | Biological process | MAPK cascade |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0031434 | Molecular function | mitogen-activated protein kinase kinase binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0005515 | Molecular function | protein binding |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0005078 | Molecular function | MAP-kinase scaffold activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004672 | Molecular function | protein kinase activity |
Gene name | KSR2 |
Protein name | Kinase suppressor of Ras 2 (hKSR2) (EC 2.7.11.1) |
Synonyms | |
Description | FUNCTION: Location-regulated scaffold connecting MEK to RAF. Has very low protein kinase activity and can phosphorylate MAP2K1 at several Ser and Thr residues with very low efficiency (in vitro). Acts as MAP2K1/MEK1-dependent allosteric activator of BRAF; upon binding to MAP2K1/MEK1, dimerizes with BRAF and promotes BRAF-mediated phosphorylation of MAP2K1/MEK1 . Interaction with BRAF enhances KSR2-mediated phosphorylation of MAP2K1 (in vitro). Blocks MAP3K8 kinase activity and MAP3K8-mediated signaling. Acts as a negative regulator of MAP3K3-mediated activation of ERK, JNK and NF-kappa-B pathways, inhibiting MAP3K3-mediated interleukin-8 production. . |
Accessions | ENST00000339824.7 [Q6VAB6-1] Q6VAB6 |